Table 1.

Characteristics of Women With CIN2+ According to Detection of Human Papillomavirus Type 16 or 18, HPV-IMPACT, United States, 2008–2014

Characteristic	HPV-16/18–Positive Cases (n = 1,561)		HPV-16/18–Negative Casesa (n = 1,739)		P Valueb
	No.	%	No.	%
Year of diagnosis					<0.001
2008–2010	897	57.5	813	46.8
2011–2014	664	42.5	926	53.2
Age at diagnosis, years					0.079
18–20	99	6.3	124	7.1
21–24	587	37.6	718	41.3
25–29	692	44.3	716	41.2
30–34	183	11.7	181	10.4
Birth cohort					<0.001
1979–1986	1,080	69.2	1,071	61.6
1987–1995	481	30.8	668	38.4
Age at vaccinationc, years					<0.001
12–18	33	21.3	169	40.8
19–22	59	38.1	141	34.1
23–26	63	40.6	104	25.1
Diagnosis					<0.001
CIN grade 2	631	40.4	1,190	68.4
CIN grade 2/3	253	16.2	222	12.8
CIN grade 3/AIS	677	43.4	327	18.8
Race/ethnicity					<0.001
Non-Hispanic white	974	62.4	917	52.7
Non-Hispanic black	197	12.6	353	20.3
Hispanic	148	9.5	195	11.2
Other	140	9.0	148	8.5
Missing data	102	6.5	126	7.2
Surveillance site					<0.001
California	152	9.7	174	10.0
Connecticut	414	26.5	592	34.0
New York	519	33.2	505	29.0
Oregon	254	16.3	263	15.1
Tennessee	222	14.2	205	11.8
Type of health insurance					0.003
Private	877	56.2	950	54.6
Public	347	22.2	466	26.8
Other/none	97	6.2	113	6.5
Missing data	240	15.4	210	12.1
No. of HPV doses received ≥24 months before screening					<0.001
0	1,406	90.1	1,325	76.2	0
1	47	3.0	89	5.1	1
2	35	2.2	73	4.2	2
3	73	4.7	252	14.5	3

Abbreviations: AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia; CIN2+, CIN grade 2, 2/3, or 3 and AIS; HPV, human papillomavirus; HPV-IMPACT, Human Papillomavirus Vaccine Impact Monitoring Project.

^aThe HPV-16/18–negative group included women with lesions of other HPV types or no types detected.

^bχ² test.

^cAmong vaccinated women only (155 HPV-16/18–positive cases and 414 HPV-16/18–negative cases).